WILL ANGIOPLASTY FOR M.S. PATIENTS EVER GET A FAIR TRIAL ?

How can we trust the M.S. Society of Canada or their researchers to promote
or investigate CCSVI if almost all of the major players have contracts

with numerous pharmaceutical companies ?

Below is a list of the
professional disclosures from the ECTRIMS conference in Sweden in

October of 2010. I`ve shortlisted the number of neurologists involved to

those who currently serve on a committee with the MS Society of Canada,

the committee of experts appointed by the Canadian Institutes of

Health Research or who are participating either as lead investigator or

secondary investigator in one of the CCSVI studies funded by the MS

Society of Canada.

CANADIAN MS NEUROLOGISTS DOING RESEARCH AND PRESENTING AT THE ECTRIMS CONFERENCE IN SWEDEN

LIST OF DISCLOSURES FROM THE ABSTRACTS OF THE ETRTIMS CONFERENCE
ALL PAGE REFERENCES ARE TO THE FOLLOWING DOCUMENT

http://msj.sagepub.com/content/16/10_suppl/S7.citation

......................................................................................................
1.
DR. V.W. YONG, Chair of the Canadian MS Society Medical Advisory

Board, Member of the Canadian MS Society Biomedical Research Grants

Review Committee, and Member of the Expert Committee to the Canadian

Institute of Health Research that refused to fund clinical trials in

Canada

PAGE S310

Disclosure: VW Yong has received honoraria from Teva Neuroscience and Bayer
Healthcare Pharmaceuticals.

.......................................................................................................
2.
DR. ANTHONY FEINSTEIN, Member of the Canadian MS Society Medical

Advisory Board and the Clinical and Population Health Research Grants

Review Committee

PAGE S11

Disclosure: Dr. Feinstein has received honoraria from Merck Serono, Bayer
HealthCare Pharmaceuticals and Teva Neuroscience.

.......................................................................................................
3.
DR. MARK S. FREEDMAN,Member of the Canadian MS Society Medical Advisory

Board, Participant Researcher of one of the studies funded by the MS

Society of Canada in the $ 2.4 million.

PAGE S23

Disclosure: Dr Freedman has received grant support from Genzyme, and has acted
as an advisor/consultant/steering committee member or speaker for
Bayer, Biogen Idec, Teva, Merck Serono, Novartis and sanofi-aventis.

PAGE S119

Disclosure: M Freedman has received personal compensation for serving as a con-
sultant for BioMS, Bayer, Novartis, Merck Serono and has received
honoraria from Bayer, Pfizer, EMDSerono, Teva, Biogen Idec, and
Genentech.

PAGE S280

Disclosure: M Freedman has received personal compensation for serving as a con-
sultant for BioMS, Bayer, Novartis, Merck Serono and has received
honoraria from Bayer, Pfizer, EMDSerono, Teva, Biogen Idec, and
Genentech.

PAGE S291

Disclosure: Mark Freedman has received research support from Genzyme and has
acted as advisor/consultant/steering committee member or speaker
for Bayer, Biogen Idec, Teva, Merck Serono, Novartis, sanofi-aventis
Hadj Benzerdjeb is an employee of sanofi-aventis.

PAGE S348

Disclosure: Dr Freedman has received grant support from Genzyme, and has acted
as an advisor/consultant/steering committee member or speaker for
Bayer, Biogen Idec, Teva, Merck Serono, Novartis and sanofi-aventis.

......................................................................................................
4.
DR. LUANE METZ, Member of the Multiple Sclerosis Society of Canada

Medical Advisory Board and the Clinical and Population Health Research

Grants Review Committee

PAGE: S152

Disclosure: Dr. Metz has nothing to disclose with respect to this trial, but has
received research funding from the MS Society of Canada,
Neuroscience Canada, and the Network of Centres for Excellence
(the Stem Cell Network) and from several philanthropists through
the Hotchkiss Brain Institute, and has consulted to Teva
Neuroscience, Biogen-Idec, EMD-Serono, Novartis, and Bayer.

PAGE : S242

Disclosure: O. Cedile, M. Løbne, H. Toft-Hansen and T. Owens have nothing to
disclose.

.......................................................................................................
5.
DR. JACK P. ANTEL, Member of the Canadian MS Medical Advisory Board,

and Member of the Expert Committee to the Canadian Institute of Health

Research that refused to fund clinical trials in Canada

PAGE: S157

Disclosure: G. John, A. Bar-Or and J. Antel are recipients of a research grant from
Teva Pharmaceuticals.


......................................................................................................
6.
DR. PAUL O’CONNOR, Member of the Canadian MS Medical Advisory Board,

Member of the Canadian MS Society Biomedical Research Grants Review

Committee, and Member of the Expert Committee to the Canadian Institute

of Health Research that refused to fund clinical trials in Canada

PAGE: S23

Disclosure: Paul O’Connor has received consulting fees and/or research support
for MS trials from Actelion, Bayer, Biogen Idec, BioMS, Cognosci,
Daiichi Sankyo, EMD Serono, Genentech, Genmab, Novartis, Roche,
sanofi-aventis, Teva and Warburg Pincus.

PAGE: S34

Disclosure: Dr O’Connor has received support in the form of consultation fees or
study grant support from the following companies: Bayer, Biogen
Idec, EMD Serono, Novartis, Sanofi Aventis, Actelion, Eli Lilly,
Genentech, Roche, and Warburg Pincus.

PAGE: S120

P O’Connor has received personal compensation for consulting from
Biogen Idec, Bayer, Genentech, Roche, Teva, sanofi avventis, and
Novartis. He has received grant support from Bayer, Genentech,
sanofi aventis, BioMS, and Novartis.

PAGE: S142

Paul O’Connor has received consulting fees and/or research support
for MS trials from Actelion, Bayer, Biogen Idec, BioMS, Cognosci,
Daiichi Sankyo, EMD Serono, Genentech, Genmab, Novartis, Roche,
sanofi-aventis, Teva and Warburg Pincus.

PAGE: S143

Disclosure: P O’Connor has received consulting fees from Biogen Idec, Sanofi-
Aventis, Novartis, EMD Serono, Bayer, Teva Neuroscience and
Genentech.

PAGE: S147

Disclosure: Paul O’Connor Consulting fees from Biogen Idec, Sanofi Aventis,
Novartis, EMD Serono, Bayer, Teva Neuroscience, Genentech

PAGE: S159

Disclosure: P O’Connor has received compensation for consulting from Biogen
Idec, Bayer, Genentech, Roche, Teva, sanofi-aventis, Novartis; and
grant support from Bayer, Genentech, sanofi-aventis, BioMS, and
Novartis.

PAGE: S170

Disclosure: P O’Connor has received consultancy and research grant support from
Bayer, Biogen-Idec, EMD Serono, Teva, Genentech, Roche, Sanofi-
Aventis and Novartis.

PAGE: S290

Disclosure: Paul O’Connor Consulting fees from Biogen Idec, Sanofi Aventis,
Novartis, EMD Serono, Bayer, Teva Neuroscience, Genentech

PAGE: S291

Disclosure: Paul O’Connor has received consulting fees and/or research support
for MS trials from Actelion, Bayer, Biogen Idec, BioMS, Cognosci,
Daiichi Sankyo, EMD Serono, Genentech, Genmab, Novartis, Roche,
sanofi-aventis, Teva and Warburg Pincus.

PAGE: S295

Disclosure: Paul O’Connor Consulting fees from Biogen Idec, Sanofi Aventis,
Novartis, EMD Serono, Bayer, Teva Neuroscience, Genentech

PAGE: S348

Disclosure: Paul O’Connor has received consulting fees and/or research support
for MS trials from Actelion, Bayer, Biogen Idec, BioMS, Cognosci,
Daiichi Sankyo, EMD Serono, Genentech, Genmab, Novartis, Roche,
sanofi-aventis, Teva and Warburg Pincus.

......................................................................................................
7. DR. JODIE BURTON, Member of the Biomedical Research Grants Review Committee, MS Society of Canada

PAGE: S152

Disclosure: Dr. Burton has nothing to disclose with respect to this trial, but has
but has received research support from Direct-MS, unrestricted travel
and educational support from TEVA Neuroscience Canada, Biogen
Idec Canada and EMD Serono and has served on advisory boards for
Biogen Idec Canada.

.....................................................................................................
8. The name of this neurologist was removed as this person had no disclosures.

.....................................................................................................
9.
DR. ANTHONY TRABOULSEE, Member of the Expert Committee to the Canadian

Institute of Health Research that refused to fund clinical trials in

Canada, , Recipient and Principal Researcher of one of the studies

funded by the MS Society of Canada in the $ 2.4 million.

PAGE: S111

Disclosure: Anthony Traboulsee received honoraria for data safety monitoring
committee participation from Merck Serono and Daiichi, honoraria
for lectures from Bayer, Merck Serono, Teva Neurosciences and
receives research support from the Canadian Institutes for Health
Research and the Multiple Sclerosis Society of Canada.

PAGE: S142

Disclosure: Anthony Traboulsee has received personal compensation from: Merck
Serono
for data safety monitoring board (DSMB) membership and for co-chairing a

symposium; Bayer Health Care for speaking; TevaNeurosciences for

chairing a symposium; Neura as a member of an editorial advisory board;

Daiichi for DSMB membership.

PAGE: S261

Disclosure: Anthony Traboulsee received honoraria for data safety monitoring
committee participation from Merck Serono and Daiichi, honoraria
for lectures from Bayer, Merck Serono, Teva Neurosciences and
receives research support from the Canadian Institutes for Health
Research and the Multiple Sclerosis Society of Canada.

.........................................................................................................
10.
DR. AARON MILLER, Member of the Expert Committee to the Canadian

Institute of Health Research that refused to fund clinical trials in

Canada

PAGE: S23

Disclosure: Dr Miller has received research support from Acorda Therapeutics,
BiogenIdec, Genentech, Genzyme, Sanofi-aventis, and Teva
Neuroscience; has served as a consultant to Acorda Therapeutics,
BiogenIdec, BioMarin, Daiichi-Sankyo, EMD Serono, Glaxo Smith
Kline, Merck Serono, Novartis, ONO, and Teva Neuroscience; and
on the speakers bureau for Acorda Therapeutics, Biogen Idec, EMD
Serono, Pfizer, and Teva Neuroscience.

PAGE: S348

Disclosure: Dr Miller has received research support from Acorda Therapeutics,
BiogenIdec, Genentech, Genzyme, Sanofi-aventis, and Teva
Neuroscience; has served as a consultant to Acorda Therapeutics,
BiogenIdec, BioMarin, Daiichi-Sankyo, EMD Serono, Glaxo Smith
Kline, Merck Serono, Novartis, ONO, and Teva Neuroscience; and
on the speakers bureau for Acorda Therapeutics, Biogen Idec, EMD
Serono, Pfizer, and Teva Neuroscience.

.....................................................................................................
11.
DR. DOUGLAS ARNOLD, Member of the Expert Committee to the Canadian

Institute of Health Research that refused to fund clinical trials in

Canada, Participant Researcher of one of the studies funded by the MS

Society of Canada in the $ 2.4 million.

PAGE: S58

Disclosure: Dr. D.L. Arnold has received honoraria from serving on the scientific
advisory boards of Biogen Idec and Genentech; holds a patent
(Method of Evaluating the Efficacy of Drug on Brain Nerve Cells);
has received speaking fees from Biogen Idec, Genentech, the MS
Forum, and the University of South Florida College of Medicine; has
served as a paid consultant for Biogen Idec, Eisai Medical Research
Inc., Genentech, MS Forum, NeuroRx Research, Novartis, and Teva
Neuroscience; and has received research support from Biogen Idec,
the Canadian Institutes of Health Research

PAGE: S107

Disclosure: Douglas Arnold is the holder of research grants from the CIHR and the
MSSC.

PAGE: S110

Disclosure: Douglas Arnold is the holder of research grants from the CIHR and the
MSSC and thanks Biogen Idec and Genentech for allowing us access to
their clinical trial data.

PAGE: S159

Disclosure: D Arnold has received compensation and/or support for research
activities from Bayer-Schering, Biogen Idec, Genentech, NeuroRx
Research, Roche, and Teva Neuroscience.

PAGE: S201

Disclosure: DL Arnold has received honoraria from serving on the scientific advi-
sory boards of Biogen Idec and Genentech; holds a patent (Method of
Evaluating the Efficacy of Drug on Brain Nerve Cells); has
received speaking fees from Biogen Idec, Genentech, the MS Forum,
and the University of South Florida College of Medicine; has served as
a paid consultant for Biogen Idec, Eisai Medical
Research Inc., Genentech, MS Forum, NeuroRx Research, Novartis,
and Teva Neuroscience; and has received research support from
Biogen Idec, the Canadian Institutes of Health Research
(PI: Grant MOP84367; Coinvestigator: Grant MOP 15630), and the
Multiple Sclerosis Society of Canada


.....................................................................................................
12.
DR. BRENDA BANWELL, Member of the Expert Committee to the Canadian

Institute of Health Research that refused to fund clinical trials in

Canada, Recipient and Principal Researcher of one of the studies funded

by the MS Society of Canada in the $ 2.4 million.

PAGE: S19

Disclosure: B Banwell has received speaker’s honoraria from Merk-Serono, Teva
Neuroscience, and Biogen-IDEC.

PAGE: S58

Disclosure: Dr. B. Banwell has received speaker’s honoraria from Merk-Serono,
Teva Neuroscience, and Biogen-IDEC. Dr. B Banwell serves as an
Editor for Multiple Sclerosis, for which she received no remuneration.

PAGE: S201

Disclosure: B Banwell has received speaker’s honoraria from Merk-Serono, Teva
Neuroscience, and Biogen-IDEC. Dr. B Banwell serves as an Editor for
Multiple Sclerosis, for which she received no remuneration.

PAGE: S216

Disclosure: Dr. B. Banwell has received speaker’s honoraria from Merk-Serono,
Teva Neuroscience, and Biogen-IDEC. Dr. B Banwell serves as an
Editor for Multiple Sclerosis, for which she received no remuneration.

........................................................................................................
13.
DR. JERRY WOLINSKY, Member of the Expert Committee to the Canadian

Institute of Health Research that refused to fund clinical trials in

Canada

PAGE: S23

Disclosure: Over the last 12 months, Dr. Wolinsky has served on advisory boards
or data monitoring committees, has consulting agreements, or
received speaker honoraria from Acorda Therapeutics, Bayer
HealthCare, Consortium of MS Clinics, Eli Lilly, EMD Serono, Facet
Biotech, Johns Hopkins University, Medscape CME, Novartis,
Peptimmune, sanofi-aventis, Serono Symposia International
Foundation, Teva and Teva Neurosciences, the National Multiple
Sclerosis Society, Northwestern University, the University of Buffalo,
the University of South Florida Professionals Conferencing and UCB;
royalties for outlicensed monoclonal antibodies through the UTHSCH
to Millipore (Chemicon International) Corporation since 1993; and
receives research or contractual support from the Clayton Foundation
for Research, the NIH [2 U01 NS045719-06 (PI of the subcontract to
UTHSCH for image analysis), 2RO1-EB002095-06A1 (Co-I)], and
sanofi-aventis; he was compensated for his efforts as an Associate
Editor for ACP Medicine, BC Decker.

PAGE: S159

Disclosure: J Wolinsky has received compensation from Antisense Therapeutics,
Ltd., Genentech, Inc., EMD Serono, Novartis, sanofi-aventis, Teva
Pharmaceuticals, Teva Neurosciences, and UCB for consulting ser-
vices. Dr. Wolinsky has received compensation from BCDecker for
serving as an Associate Editor of ACP Medicine. He has also received
royalty payments from Chemicon for licensed technology and finan-
cial support for research activities from sanofi-aventis and the
National Institutes of Health.

PAGE: S306

Disclosure: .Wolinsky has received compensation from Novartis as an advisor.

........................................................................................................
14.
DR. RUTH ANN MARIE, Member of the Expert Committee to the Canadian

Institute of Health Research that refused to fund clinical trials in

Canada, Participant Researcher of one of the studies funded by the MS

Society of Canada in the $ 2.4 million.

PAGE: S334

Disclosure: Ruth Ann Marrie has consulted for Berlex, BioMS, EMD Serono and
Sanofi Aventis.

PAGE: S335

Disclosure: Ruth Ann Marrie has consulted for Berlex, BioMS, EMD Serono and
Sanofi Aventis.

.........................................................................................................
15. DR. AMIT BAR OR, Participant Researcher of one of the studies funded by the MS Society of Canada in the $ 2.4 million.

PAGE: S291

Disclosure: Amit Bar-Or has received research support from Biogen-Idec,
Genentech and Teva Neuroscience, and received fees for consulting,
serving on scientific advisory boards and/or speaking activities from
Bayer, Bayhill Therapeutics, Berlex, Biogen-Idec, BioMS, Diogenix, Eli-
Lilly, Genentech, GSK, Guthy-Jackson/GGF, Merck-Serono, Novartis,
Ono Pharmacia, Roche, sanofi-aventis, Teva Neuroscience andWyeth.